OncoMed Pharmaceuticals (OMED) announced that it has completed the enrollment of 207 subjects in its Phase 2 clinical trial, YOSEMITE, evaluating as first-line treatment of metastatic pancreatic cancer. Top-line data should be available in the first half of next year. The primary endpoint is progression-free survival. Secondary endpoints include overall survival, response rate and biomarker analyses.